Dose-Finding Study of a CEA-Targeting Agent, SGM-101, for Intraoperative Fluorescence Imaging of Colorectal Cancer

202071 citationsJournal Articlehybrid Open Access

Authors

Kim S. de Valk · Centre for Human Drug Research

Marion M. Deken · Leiden University Medical Center

Dennis P. Schaap · Radboud University Nijmegen

R.P. Meijer · Leiden University Medical Center

Leonora S. F. Boogerd · Leiden University Medical Center

Charlotte E.S. Hoogstins · Leiden University Medical Center

Maxime JM. van der Valk

Abstract

The optimal imaging dose was established at 10 mg 4 days before surgery. The results accentuate the potential of SGM-101 and designated a promising base for the multinational phase III study, which enrolled the first patients in June 2019.

Topics & Keywords

Colorectal Cancer Surgical Treatments Nanoplatforms for cancer theranostics Cardiac, Anesthesia and Surgical Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Surgical Oncology

Volume 28, Issue 3, pp. 1832-1844

DOI: 10.1245/s10434-020-09069-2

Field-Weighted Citation Impact: 3.10